Table 8. Sensitivity analyses: Treatment outcomes over time, by group (N = 36)a.

Gp 1: Add on Ayurveda Group, Gp 2: Standard of Care Group

^a Population with last observation carried forward for 20% of missing values lost to follow-up. * Values at a 95% confidence interval where the level of significance, α= 0.05. ^b p-values assessed using the method of robust regression controlled for baseline differences with treatment group as covariate has been used to test differences between the treatment groups unless otherwise noted. ^c p-values assessed using ANCOVA at 95 CI. ** Parameter not assessed as per the protocol; NA: Not Applicable

Parameter	Days of therapy	Gp 1			Gp 2			p-value	Estimate
		N	Mean	SD	N	Mean	SD
Interleukin-6b	Baseline	22	65.9	43.4	14	56.3	43.6	-	-
	14	22	6.3	6.8	14	18.2	29.6	0.029*	-14.58
	28	NA**	NA**	NA**	NA**	NA**	NA**	NA**	NA**
	60	22	5.3	5.6	14	5.9	8.5	0.58	0.14
C-reactive proteinb	Baseline	22	7.5	5.7	14	8.9	7.0	-	-
	14	22	2.4	4.7	14	6.5	8.9	0.037*	-3.65
	28	NA**	NA**	NA**	NA**	NA**	NA**	NA**	NA**
	60	22	1.0	1.7	14	1.9	4.4	0.67	0.78
Neutrophils-Lymphocytes Ratiob	Baseline	22	7.8	3.9	14	7.9	3.5	-	-
	14	22	6.6	3.7	14	8.5	4.4	0.04*	-1.74
	28	22	3.9	2.3	14	5.1	3.9	0.17	-1.16
	60	22	3.4	2.3	14	4.8	3.1	0.11	-1.26
HS- Troponinb	Baseline	NA**	NA**	NA**	NA**	NA**	NA**	NA**	NA**
	14	22	10.6	5.6	14	11.7	7.2	-	-
	28	22	9.1	3.9	14	13.7	12.7	0.01*	-3.5
	60	22	7.7	3.8	14	11.8	8.7	0.03*	-3.4
HRCT CORADS scorec	Baseline	16	13.4	4.6	9	13.8	2.8	-	-
	14	NA**	NA**	NA**	NA**	NA**	NA**	NA**	NA**
	28	NA**	NA**	NA**	NA**	NA**	NA**	NA**	NA**
	60	16	6.3	5.0	9	10.9	5.9	0.046*	-4.8